Edwards MITRIS RESILIA Valve Receives CE Mark for Mitral Replacement Surgeries
Edwards Lifesciences announced it received CE Mark for the MITRIS RESILIA valve, a tissue valve replacement specifically designed for the heart's mitral position.
Latest Press Releases
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
Focal Medical Complete Development of a Therapeutic System to Deliver Gemcitabine Directly to the Pancreas
Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products announced successful completion of the nonclinical development phase of Focal Medical’s Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003).
Lubrizol Launches Carbopol® Polymers for Nutraceuticals with New EU Food Grade Approval
The Lubrizol Corporation announces the new EU food-grade approval for Carbopol® Polymers. The approval in the EU will enable nutraceutical manufacturers the ability to differentiate their portfolio and create unique new product claims.
Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
Celltrion Group announced that the merger agreement between Celltrion, Inc. was approved at the extraordinary general meeting of shareholders (“EGM”) of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.
Seegene Reinforces Commitment to Strong ESG Management with 100% Recyclable
Seegene's eco-friendly shipping box is composed of 12-paper layers, biodegradable films, recycled PET packaging, a vacuum insulation panel, dry ice, and ice packs. The materials are either 100% renewable or certified as "green" via organizations such as the Forest Stewardship Council (FSC) and the Ministry of Environment in Korea.
TriasMD Acquires Pinnacle Surgery Center to Bring DISC
TriasMD, a musculoskeletal management company and parent of the DISC Surgery Centers, has announced its acquisition of Walnut Creek-based Pinnacle Surgery Center ("Pinnacle").
Empaveli is the first treatment for PNH that binds to the complement protein C3
Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3.
Successful Launch of JVM's Next-Generation Automated Drug Dispensing System
A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.
Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics
Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen's innovative CAR-GPC3 T-cell therapy.